Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatocellular carcinoma.

D F Schafer1, M F Sorrell

  • 1Department of Internal Medicine, University of Nebraska Medical Center, Omaha 66198-2009, USA.

Lancet (London, England)
|April 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut permeability and mucosal inflammation: bad, good or context dependent.

Mucosal immunology·2017
Same author

NIH consensus development statement on management of hepatitis B.

NIH consensus and state-of-the-science statements·2008
Same author

Finding a home for cell transplants: location, location, location.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2006
Same author

De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation.

Transplantation proceedings·2004
Same author

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.

Transplantation proceedings·2003
Same author

Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study.

Transplantation proceedings·2003
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Hepatocellular carcinoma (HCC) is a fatal liver disease complication, but its main causes, Hepatitis B and C, are preventable. Vaccination and improved medical techniques can interrupt viral transmission, offering hope for reducing liver cancer incidence.

Area of Science:

  • Hepatology
  • Viral Oncology
  • Public Health

Background:

  • Hepatocellular carcinoma (HCC) is a terminal complication of chronic liver disease.
  • Current treatments for HCC are largely palliative, with rare long-term survival.
  • The primary global causes of HCC are known and preventable viral infections.

Purpose of the Study:

  • To highlight the preventable nature of major Hepatocellular carcinoma causes.
  • To emphasize the importance of interrupting Hepatitis B and C virus transmission.
  • To discuss current strategies for preventing viral hepatitis-related liver cancer.

Main Methods:

  • Review of global epidemiological data on Hepatocellular carcinoma.
  • Analysis of Hepatitis B and C virus transmission dynamics.

Related Experiment Videos

  • Evaluation of public health interventions for viral hepatitis prevention.

    • Main Results:

    • Hepatitis B and C viruses are exclusively human pathogens with no non-human reservoirs.
    • Hepatitis B virus infection can be prevented through vaccination.
    • Improvements in medical techniques can reduce Hepatitis C transmission, though a vaccine is not yet available.

    Conclusions:

    • Hepatocellular carcinoma incidence can be significantly reduced by preventing Hepatitis B and C infections.
    • Vaccination against Hepatitis B is a key strategy for HCC prevention.
    • Continued advancements in medical practices are crucial for controlling Hepatitis C and mitigating its role in liver cancer development.